Objective:

To summarize key clinical updates and findings from prostate cancer studies presented at ESMO 2025, emphasizing their significance for treatment strategies.

Key Findings:

• NSRAD did not meet its primary endpoint of improved metastasis-free survival (MFS) with enzalutamide, raising concerns about its efficacy.
• Enzalutamide improved PSA progression-free survival but did not show a significant impact on overall survival.
• Patients with node-positive disease or indications for pelvic field radiation showed improved MFS with enzalutamide, suggesting a targeted benefit.
• The EMBARK study demonstrated improved overall survival with enzalutamide plus ADT compared to ADT alone, reinforcing its role in high-risk biochemical relapse.

Interpretation:

The findings suggest that while enzalutamide may not be necessary for all patients with localized prostate cancer, specific subgroups, such as those with node-positive disease, may benefit from its addition to standard therapy.

Limitations:

• NSRAD's primary endpoint was not met, raising questions about the generalizability of results and the potential for selection bias.
• Differences in patient populations between NSRAD and other studies like STAMPEDE may affect comparisons and the applicability of findings.

Conclusion:

The studies highlight the importance of personalized treatment approaches in prostate cancer, particularly identifying which patients may benefit from intensified hormone therapy, and underscore the need for further research.